Suppr超能文献

喹啉衍生物作为抗SARS-CoV-2蛋白酶抑制剂的设计、合成及分子动力学模拟研究

Design, synthesis, and molecular dynamics simulation studies of quinoline derivatives as protease inhibitors against SARS-CoV-2.

作者信息

Singh Vishal K, Chaurasia Himani, Kumari Priyanka, Som Anup, Mishra Richa, Srivastava Ritika, Naaz Farha, Singh Anuradha, Singh Ramendra K

机构信息

Bioorganic Research Laboratory, Department of Chemistry, University of Allahabad, Prayagraj, India.

Centre of Bioinformatics, University of Allahabad, Prayagraj, India.

出版信息

J Biomol Struct Dyn. 2022;40(21):10519-10542. doi: 10.1080/07391102.2021.1946716. Epub 2021 Jul 12.

Abstract

A new series of quinoline derivatives has been designed and synthesized as probable protease inhibitors (PIs) against severe acute respiratory syndrome coronavirus 2. studies using DS v20.1.0.19295 software have shown that these compounds behaved as PIs while interacting at the allosteric site of target Mpro enzyme (6LU7). The designed compounds have shown promising docking results, which revealed that all compounds formed hydrogen bonds with His41, His164, Glu166, Tyr54, Asp187, and showed π-interaction with His41, the highly conserved amino acids in the target protein. Toxicity Prediction by Komputer Assisted Technology results confirmed that the compounds were found to be less toxic than the reference drug. Further, molecular dynamics simulations were performed on compound and remdesivir with protease enzyme. Analysis of conformational stability, residue flexibility, compactness, hydrogen bonding, solvent accessible surface area (SASA), and binding free energy revealed comparable stability of protease: complex to the protease: remdesivir complex. The result of hydrogen bonding showed a large number of intermolecular hydrogen bonds formed between protein residues (Glu166 and Gln189) and ligand , indicating strong interaction, which validated the docking result. Further, compactness analysis, SASA and interactions like hydrogen-bonding demonstrated inhibitory properties of compound similar to the existing reference drug. Thus, the designed compound might act as a potential inhibitor against the protease enzyme.Communicated by Ramaswamy H. SarmaHighlightsQuinoline derivatives have been designed as protease inhibitors against SARS-CoV-2.The compounds were docked at the allosteric site of SARS-CoV-2-Mpro enzyme (PDB ID: 6LU7) to study the stability of protein-ligand complex.Docking studies indicated the stable ligand-protein complexes for all designed compounds.The Toxicity Prediction by Komputer Assisted Technology protocol in DS v20.1.0.19295 software was used to evaluate the toxicity of the designed quinoline derivatives.Molecular dynamics studies indicated the formation of stable ligand-Mpro complexes.

摘要

已设计并合成了一系列新的喹啉衍生物,作为针对严重急性呼吸综合征冠状病毒2的潜在蛋白酶抑制剂(PIs)。使用DS v20.1.0.19295软件进行的研究表明,这些化合物在与靶标Mpro酶(6LU7)的变构位点相互作用时表现为蛋白酶抑制剂。所设计的化合物显示出有前景的对接结果,这表明所有化合物均与His41、His164、Glu166、Tyr54、Asp187形成氢键,并与靶蛋白中高度保守的氨基酸His41表现出π相互作用。通过计算机辅助技术进行的毒性预测结果证实,这些化合物的毒性低于参考药物。此外,对化合物和瑞德西韦与蛋白酶进行了分子动力学模拟。对构象稳定性、残基灵活性、紧凑性、氢键、溶剂可及表面积(SASA)和结合自由能的分析表明,蛋白酶:复合物与蛋白酶:瑞德西韦复合物具有相当的稳定性。氢键结果表明,蛋白质残基(Glu166和Gln189)与配体之间形成了大量分子间氢键,表明相互作用强烈,这验证了对接结果。此外,紧凑性分析、SASA以及氢键等相互作用证明了化合物与现有参考药物相似的抑制特性。因此,所设计的化合物可能作为蛋白酶的潜在抑制剂。由Ramaswamy H. Sarma传达重点喹啉衍生物已被设计为针对SARS-CoV-2的蛋白酶抑制剂。这些化合物对接在SARS-CoV-2-Mpro酶的变构位点(PDB ID:6LU7)以研究蛋白质-配体复合物的稳定性。对接研究表明所有设计的化合物都有稳定的配体-蛋白质复合物。使用DS v20.1.0.19295软件中的计算机辅助技术协议进行毒性预测,以评估所设计的喹啉衍生物的毒性。分子动力学研究表明形成了稳定的配体-Mpro复合物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验